NCT06129955 2023-11-13
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
Clinical Trials
62 trialsNCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT05879471 2023-07-24
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05879497 2023-07-13
68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05879510 2023-07-13
68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05902377 2023-06-15
68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03741426 2023-06-07
WIRE
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Unknown
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02613819 2022-11-18
FASTRACK II
Trans Tasman Radiation Oncology Group
Phase 2 Unknown
NCT04913025 2022-09-21
REFINE
University College, London
Phase 2 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03177239 2022-02-16
UNISoN
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02689167 2021-11-29
SURF
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT05124431 2021-11-18
ALTER-UC-001
Fudan University
Phase 2 Unknown
NCT01444807 2021-09-17
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04534998 2021-09-13
ROBOCOP
Universitätsmedizin Mannheim
Phase 2 Unknown
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04958473 2021-07-12
SAARCC
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04718584 2021-01-22
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Dragonboat Biopharmaceutical Company Limited
Phase 2 Unknown
NCT04714697 2021-01-19
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
Asan Medical Center
Phase 2 Unknown
NCT04134182 2020-12-23
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT04644432 2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2 Unknown
NCT03987698 2020-07-07
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT04146831 2020-05-12
Sintilimab in FH-deficient Renal Cell Carcinoma
West China Hospital
Phase 2 Unknown
NCT03592199 2019-09-04
SuAx
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT04049344 2019-08-08
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03341845 2018-05-21
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
The Netherlands Cancer Institute
Phase 2 Unknown
NCT02072044 2017-12-29
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT02330783 2017-05-09
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT02774200 2016-05-17
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02398552 2016-03-01
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01791387 2015-02-03
DILIGENCE-1
Auckland District Health Board
Phase 2 Unknown
NCT02324803 2014-12-24
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Southern China Urology Cancer Consortium
Phase 2 Unknown
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT01577784 2014-03-12
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00301990 2014-01-10
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00717587 2014-01-10
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00030888 2014-01-06
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002846 2013-12-19
Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002847 2013-12-19
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00080977 2013-12-19
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00093522 2013-12-19
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002589 2013-12-18
Lymphocyte Therapy in Treating Patients With Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003181 2013-12-04
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003604 2013-11-06
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003664 2013-11-06
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005038 2013-09-20
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00626509 2013-08-12
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown